Pharmacological properties of the Cys23Ser single nucleotide polymorphism in human 5-HT2C receptor isoforms

Pharmacogenomics Journal

Volumn 5, Issue 4, 2005, Pages 244-254

  Fentress, H M ^a   Grinde, E ^b   Mazurkiewicz, J E ^b   Backstrom, J R ^a   Herrick Davis, K ^b   Sanders Bush, Elaine ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

Author keywords

G protein coupled receptor; Genetics; RNA editing; Serotonin; Serotonin 2C receptor

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; CLOZAPINE; CYSTEINE; FLUOXETINE; ISOPROTEIN; MIANSERIN; SERINE; SEROTONIN; SEROTONIN 2C RECEPTOR;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BIOTINYLATION; CELL STRAIN 3T3; CELL STRAIN COS7; CELL STRAIN HEK293; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DIMERIZATION; DOSE RESPONSE; DRUG RECEPTOR BINDING; FIBROBLAST; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE LINKAGE DISEQUILIBRIUM; HUMAN; HUMAN CELL; MOLECULAR IMAGING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN HYDROLYSIS; PROTEIN LOCALIZATION; SINGLE NUCLEOTIDE POLYMORPHISM; STRAIN DIFFERENCE;

ANIMALS; BINDING, COMPETITIVE; CELL LINE; CERCOPITHECUS AETHIOPS; CYSTEINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIGANDS; MICE; MUTAGENESIS, SITE-DIRECTED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN ISOFORMS; RECEPTOR, SEROTONIN, 5-HT2C; SERINE; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; TRANSFECTION;

EID: 23644432642     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500315     Document Type: Article

References (41)

1. Mengod G, Pompeiano M, Martinez-Mir MI, Palacios JM. Localization of the mRNA for the 5-HT2 receptor by in situ hybridization histochemistry. Correlation with the distribution of receptor sites. Brain Res 1990; 524: 139-143.
2. Giorgetti M, Tecott LH. Contributions of 5-HT(2C) receptors to multiple actions of central serotonin systems. Eur J Pharmacol 2004; 488: 1-9.
3. Chang M, Zhang L, Tam JP, Sanders-Bush E. Dissecting G protein-coupled receptor signaling pathways with membrane-permeable blocking peptides. Endogenous 5-HT(2C) receptors in choroid plexus epithelial cells. J Biol Chem 2000; 275: 7021-7029.
4. Niswender CM, Copeland SC, Herrick-Davis K, Emeson RB, Sanders-Bush E. RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity. J Biol Chem 1999; 274: 9472-9478.
5. Burns CM, Chu H, Rueter SM, Hutchinson LK, Canton H, Sanders-Bush E et al. Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature 1997; 387: 303-308.
6. Fitzgerald LW, Iyer G, Conklin DS, Krause CM, Marshall A, Patterson JP et al. Messenger RNA editing of the human serotonin 5-HT2C receptor. Neuropsychopharmacology 1999; 2: 82S-90S.
7. Herrick-Davis K, Grinde E, Niswender CM. Serotonin 5-HT2C receptor RNA editing alters receptor basal activity: implications for serotonergic signal transduction. J Neurochem 1999; 73: 1711-1717.
8. Price RD, Weiner DM, Chang MSS, Sanders-Bush E. RNA editing of the human serotonin 5-HT2C receptor alters receptor-mediated activation of G13 protein. J Biol Chem 2001; 276: 44663-44668.
9. Lander ES. The new genomics: global views of biology. Science 1996; 274: 536-539.
10. Wang DG, Fan JB, Siao CJ, Berno A, Young P, Sapolsky R et al. Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. Science 1998; 280: 1077-1082.
11. Rana BK, Shiina T, Insel PA. Genetic variations and polymorphisms of G protein-coupled receptors: functional and therapeutic implications. Annu Rev Pharmacol Toxicol 2001; 41: 593-624.
12. Palvimaki EP, Roth BL, Majasuo H, Laakso A, Kuoppamaki M, Syvalahti E et al. Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor. Psychopharmacology (Berl) 1996; 126: 234-240.
13. Roth BL, Ciaranello RD, Meltzer HY. Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors. J Pharmacol Exp Ther 1992; 260: 1361-1365.
14. Lappalainen J, Zhang L, Dean M, Oz M, Ozaki N, Yu DH et al. Identification, expression, and pharmacology of a Cys23-Ser23 substitution in the human 5-HT2c receptor gene (HTR2C). Genomics 1995; 27: 274-279.
15. Sodhi MS, Arranz MJ, Curtis D, Ball DM, Sham P, Roberts GW et al. Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport 1995; 7: 169-172.
16. Segman RH, Heresco-Levy U, Finkel B, Inbar R, Neeman T, Schlafman M et al. Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility. Psychopharmacology (Berl) 2000; 152: 408-413.
17. Lerer B, Macciardi F, Segman RH, Adolfsson R, Blackwood D, Blairy S et al. Variability of 5-HT2C receptor cys23ser polymorphism among European populations and vulnerability to affective disorder. Mol Psychiatry 2001; 6: 579-585.
18. Holmes C, Arranz MJ, Powell JF, Collier DA, Lovestone S. 5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer's disease. Hum Mol Genet 1998; 7: 1507-1509.
19. Bernier V, Bichet DG, Bouvier M. Pharmacological chaperone action on G-protein-coupled receptors. Curr Opin Pharmacol 2004; 4: 528-533.
20. Backstrom JR, Westphal RS, Canton H, Sanders-Bush E. Identification of rat serotonin 5-HT2C receptors as glycoproteins containing N-linked oligosaccharides. Mol Brain Res 1995; 33: 311-318.
21. Barker EL, Westphal RS, Schmidt D, Sanders-Bush E. Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands. J Biol Chem 1994; 269: 11687-11690.
22. Herrick-Davis K, Grinde E, Teitler M. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J Pharmacol Exp Ther 2000; 295: 226-232.
23. Niswender CM, Sanders-Bush E, Emeson RB. Identification and characterization of RNA editing events within the 5-HT2C receptor. Ann NY Acad Sci 1998; 861: 38-48.
24. Arora KK, Sakai A, Catt KJ. Effects of second intracellular loop mutations on signal transduction and internalization of the gonadotropin-releasing hormone receptor. J Biol Chem 1995; 270: 22820-22826.
25. Visiers I, Hassan SA, Weinstein H. Differences in conformational properties of the second intracellular loop (IL2) in 5HT(2C) receptors modified by RNA editing can account for G protein coupling efficiency. Protein Eng 2001; 14: 409-414.
26. Yuan X, Yamada K, Ishiyama-Shigemoto S, Koyama W, Nonaka K. Identification of polymorphic loci in the promoter region of the serotonin 5-HT2C receptor gene and their association with obesity and type II diabetes. Diabetologia 2000; 43: 373-376.
27. Deckert J, Meyer J, Catalano M, Bosi M, Sand P, DiBella D et al. Novel 5′-regulatory region polymorphisms of the 5-HT2C receptor gene: association study with panic disorder. Int J Neuropsychopharmacol 2000; 3: 321-325.
28. Sanders-Bush E, Fentress H, Hazelwood L. Serotonin 5-ht2 receptors: molecular and genomic diversity. Mol Interv 2003; 3: 319-330.
29. Okada M, Northup JK, Ozaki N, Russell JT, Linnoila M, Goldman D. Modification of human 5-HT(2C) receptor function by Cys23Ser, an abundant, naturally occurring amino-acid substitution. Mol Psychiatry 2004; 9: 55-64.
30. Wenkert D, Schoneberg T, Merendino Jr JJ, Rodriguez Pena MS, Vinitsky R, Goldsmith PK et al. Functional characterization of five V2 vasopressin receptor gene mutations. Mol Cell Endocrinol 1996; 124: 43-50.
31. Morello JP, Salahpour A, Laperriere A, Bernier V, Arthus MF, Lonergan M et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Invest 2000; 105: 887-895.
32. Shapiro DA, Kristiansen K, Weiner DM, Kroeze WK, Roth BL. Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6. J Biol Chem 2002; 277: 11441-11449.
33. Herrick-Davis K, Grinde E, Mazurkiewicz JE. Biochemical and biophysical characterization of serotonin 5-HT2C receptor homodimers on the plasma membrane of living cells. Biochemistry 2004; 43: 13963-13971.
34. Angers S, Salahpour A, Bouvier M. Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. Annu Rev Pharmacol Toxicol 2002; 42: 409-435.
35. Förster T. Zwischenmolekulare energiewanderung und fluoreszenz. Ann Physik 1948; 2: 55-75.
36. Kenworthy AK, Edidin M. Distribution of a glycosylphosphatidylinositol-anchored protein at the apical surface of MDCK cells examined at a resolution of <100 Å using imaging fluorescence resonance energy transfer. J Cell Biol 1998; 142: 69-84.
37. Wallrabe H, Elangovan M, Burchard A, Periasamy A, Barroso M. Confocal FRET microscopy to measure clustering of ligand-receptor complexes in endocytic membranes. Biophys J 2003; 85: 559-571.
38. Masellis M, Basile V, Meltzer HY, Lieberman JA, Sevy S, Macciardi FM et al. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 1998; 19: 123-132.
39. Backstrom JR, Sanders-Bush E. Generation of anti-peptide antibodies against serotonin 5-HT2A and 5-HT2C receptors. J Neurosci Methods 1997; 77: 109-117.
40. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973; 22: 3099-3108.
41. Bastiaens PI, Majoul IV, Verveer PJ, Soling HD, Jovin TM. Imaging the intracellular trafficking and state of the AB5 quaternary structure of cholera toxin. EMBO J 1996; 15: 4246-4253.